Testosterone Cream Dosing for Women: A Complete Clinical Guide

Why Women Need Testosterone at All

Testosterone is not exclusively a male hormone. Women produce 100 to 400 mcg of testosterone daily from the ovaries and adrenal glands, and serum total testosterone in reproductive-age women normally ranges from about 15 to 70 ng/dL [1]. After natural menopause, total testosterone falls by roughly 50% compared with peak reproductive years, and surgical menopause causes an even steeper drop because the ovaries are removed outright [2].

The Endocrine Society's 2014 clinical practice guideline on androgen therapy in women states: "We recommend against the general use of testosterone by women, but we suggest it may be used for postmenopausal women with hypoactive sexual desire disorder (HSDD) not explained by other causes, after detailed counseling" [3]. That guidance is conservative compared with later position statements, but it still establishes a clear clinical basis for treatment.

Low testosterone in women shows up as reduced libido, fatigue, difficulty concentrating, and loss of lean muscle mass. The 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women, endorsed by 10 major medical societies, concluded that testosterone therapy based on physiological serum levels is supported by the highest level of evidence specifically for HSDD in postmenopausal women [4]. With that framework in place, accurate dosing becomes the clinical priority.

Understanding Testosterone Cream Formulations

Testosterone cream for women is compounded (no FDA-approved product exists specifically for female dosing), usually prepared as a 0.5 to 2% concentration in a base such as pluronic lecithin organogel (PLO) or a standard transdermal cream. The most common application sites are the inner arm, inner thigh, or labia minora, and absorption varies by site and individual skin thickness [5].

A 0.5% cream delivers 0.5 mg per 0.1 mL (100 mg cream). A 1% cream delivers 1 mg per 0.1 mL. Knowing the concentration matters for dosing accuracy: prescribers should specify both the concentration (%) and the volume (mL) per application to avoid compounding ambiguity.

Percutaneous absorption of testosterone in women is highly variable, with bioavailability ranging from 8 to 30% depending on the carrier and application site [5]. This variability is why serum monitoring is not optional. It is the mechanism that separates appropriate dose titration from guesswork.

Starting Dose and Initial Titration

Most protocols begin at 0.5 to 1 mg of elemental testosterone per day. The 2019 Global Consensus Position Statement recommends targeting a total serum testosterone concentration at or below the upper limit of the normal female range, which most laboratories set at approximately 55 to 70 ng/dL [4]. Starting conservatively and titrating up protects against androgenic side effects including acne, hair loss, and clitoral enlargement, most of which are dose-dependent and reversible with dose reduction.

A practical starting protocol looks like this: apply 0.5 mg testosterone cream once daily to the inner forearm or inner thigh, rotating sites daily. Recheck total and free testosterone, sex hormone-binding globulin (SHBG), and a symptom score (such as the Female Sexual Function Index, FSFI) at 6 weeks. If total testosterone remains below 20 ng/dL and symptoms are unchanged, increase to 1 mg/day and recheck at another 6 weeks [6].

The 2019 consensus statement explicitly states: "Practitioners are advised to measure total testosterone levels before commencing therapy and at follow-up using an accurate and reliable method, preferably by liquid chromatography-tandem mass spectrometry (LC-MS/MS)" [4]. Standard immunoassays underperform at the low concentrations typical of women, which is a practical reason to request LC-MS/MS specifically.

After reaching a stable dose, monitoring can shift to every 6 months. Total testosterone should stay below 70 ng/dL to avoid supraphysiologic levels. Free testosterone above 3.5 pg/mL on LC-MS/MS warrants dose reduction regardless of symptom status [4].

Dose Ranges in Clinical Practice

The table below summarizes doses used across published trials and clinical protocols:

| Formulation | Concentration | Elemental Dose | Application Site | |---|---|---|---| | Transdermal cream | 0.5% | 0.5 to 1 mg/day | Inner arm or thigh | | Transdermal cream | 1% | 1 to 2 mg/day | Inner arm or thigh | | Transdermal cream | 2% | 2 to 4 mg/day | Inner arm, thigh, or labia | | PLO gel | 1% | 1 to 3 mg/day | Inner wrist or forearm |

The INTIMATE NM1 trial (N=261) tested a testosterone cream at 300 mcg/day (0.3 mg/day) versus placebo in naturally menopausal women with HSDD and found significant improvement in satisfying sexual events and desire at 12 weeks [7]. That 0.3 mg/day dose is lower than many compounding protocols use, which suggests that the minimum effective dose for some women is well below 1 mg/day. Titrating down from 1 mg/day, rather than starting at 0.5 mg/day, may occasionally produce androgenic side effects that could have been avoided entirely.

A study by Davis et al. published in the Journal of Clinical Endocrinology & Metabolism tested a 1% testosterone cream at 10 mg/day (very high by current standards) and found supraphysiologic levels in over 60% of subjects, confirming that doses above 5 mg/day in women are rarely justified [8]. That trial contributed to the current consensus that female-appropriate doses sit between 0.3 mg and 5 mg/day, with most women responding at 0.5 to 2 mg/day.

How SHBG Affects Testosterone Dosing

SHBG binds testosterone tightly, and oral estrogen raises SHBG substantially, which reduces free testosterone even as total testosterone stays normal. Women taking oral estradiol who also receive testosterone may need higher testosterone doses simply to achieve adequate free levels [9]. Women using transdermal estradiol have smaller SHBG increases and often respond to lower testosterone doses [9].

Checking SHBG at baseline and at every titration point gives the clinician a second lever: if SHBG is above 160 nmol/L on oral estrogen, switching to a transdermal estrogen formulation may raise free testosterone without increasing the testosterone dose at all. The Endocrine Society notes that "oral estrogen administration substantially increases hepatic SHBG production" compared with transdermal routes [3].

Women with baseline SHBG below 30 nmol/L (common in obesity or after androgenic progestin use) often achieve adequate free testosterone at doses as low as 0.3 to 0.5 mg/day and carry higher risk of androgenic side effects at standard doses. Starting these patients at 0.25 to 0.3 mg/day is reasonable [6].

Estradiol Dosing in the Same Protocol

Most women receiving testosterone cream for HRT also need estradiol, and understanding estradiol dosing helps because the two interact through SHBG (as above) and through downstream symptom expression.

Transdermal estradiol patches start at 0.025 mg/24 h (25 mcg/day), which is the lowest commercially available dose (Climara, Vivelle-Dot). Symptomatic women often need 0.05 to 0.1 mg/24 h for adequate vasomotor symptom control [10]. The Women's Health Initiative (WHI) used conjugated equine estrogen 0.625 mg/day orally, a dose now considered higher than necessary for most women [11]. Post-WHI guidelines shifted toward lower-dose transdermal estradiol because it avoids first-pass hepatic metabolism, produces lower SHBG increases, and may carry a more favorable venous thromboembolism (VTE) profile [12].

Oral estradiol (17-beta-estradiol) starts at 0.5 to 1 mg/day. Many women achieve symptom control at 1 mg/day; up to 2 mg/day is used when 1 mg/day is insufficient after 8 to 12 weeks [10]. A 2019 study in Menopause (N=872) found that transdermal estradiol at 0.05 mg/day produced serum estradiol levels of 40, 50 pg/mL, the range associated with symptom relief while keeping thrombotic risk low [12].

The North American Menopause Society (NAMS) 2022 position statement states: "Low-dose vaginal estrogen is preferred for women whose only symptoms are genitourinary, and systemic estrogen is appropriate for women with both vasomotor symptoms and genitourinary symptoms" [13].

Progesterone Dosing: Cyclic vs. Continuous

Any woman with an intact uterus receiving systemic estrogen needs a progestogen to protect the endometrium. The two main options are cyclic progesterone and continuous progesterone, and the dosing differs [14].

Cyclic protocol: Micronized oral progesterone (Prometrium) 200 mg/day for days 1, 14 of each calendar month. This schedule mimics the luteal phase and tends to produce scheduled withdrawal bleeding. The PEPI trial (N=875) showed that cyclic progesterone protected the endometrium from estrogen-induced hyperplasia over 3 years [15]. Cyclic dosing is typically preferred in perimenopausal women who still expect some menstrual irregularity.

Continuous protocol: Micronized oral progesterone 100 to 200 mg/day every night. Continuous use suppresses the endometrium without withdrawal bleeds. The 100 mg dose is standard for women on low-to-moderate estrogen doses; 200 mg/day is used when estrogen doses exceed 0.1 mg/day transdermal or 2 mg/day oral [14]. Most postmenopausal women prefer continuous dosing to avoid the monthly bleed.

Progesterone 200 mg taken at bedtime has a sedative effect via neurosteroid activity at GABA-A receptors, which is a useful feature for women with sleep disturbance but worth flagging for those who find morning brain fog problematic [16]. Switching to a morning dose or reducing to 100 mg nightly often resolves this side effect.

Putting the Full Protocol Together: A Practical Titration Framework

A typical starting regimen for a postmenopausal woman with vasomotor symptoms, low libido, and an intact uterus:

Week 0 (Baseline labs): Total testosterone (LC-MS/MS), free testosterone, SHBG, estradiol (E2), FSH, LH, CBC, CMP, fasting lipids, and if clinically indicated, mammogram and pelvic ultrasound.

Week 0 (Starting doses):

• Estradiol patch 0.05 mg/24 h, changed twice weekly
• Micronized progesterone 100 mg nightly (continuous)
• Testosterone cream 0.5% at 0.5 mg/day to inner forearm

Week 6 (First recheck): Repeat total testosterone, free testosterone, SHBG, E2, and FSFI symptom score. Adjust as follows:

• If total testosterone is below 20 ng/dL and FSFI desire domain score is below 3.0, increase testosterone cream to 1 mg/day.
• If estradiol is below 30 pg/mL and vasomotor symptoms persist, increase patch to 0.075 mg/24 h.
• If SHBG exceeds 160 nmol/L, consider switching from oral to transdermal estradiol.

Week 12 (Second recheck): Repeat full panel. If testosterone is in the target range (20 to 70 ng/dL total, 1.0, 3.5 pg/mL free) and symptoms are controlled, shift to every-6-month monitoring.

Ongoing: Annual endometrial safety check if any unscheduled bleeding occurs on continuous progesterone. Annual review of cardiovascular risk factors [13].

Monitoring for Androgenic Side Effects

The most common androgenic side effects at physiologic doses are mild acne (reported in 8 to 12% of women in testosterone trials), increased facial hair (5 to 10%), and scalp hair thinning (less than 5%) [4]. These are dose-dependent. The approach to each:

• Acne: first reduce testosterone dose by 25 to 30%; if persistent, add topical tretinoin.
• Facial hair: reduce dose; if hair is already established, laser hair removal is more effective than further dose reduction alone.
• Scalp hair thinning: rule out DHT excess by checking dihydrotestosterone levels; if elevated, dose reduction is the primary fix.

Clitoral enlargement and voice deepening are rare at physiologic doses but warrant immediate dose reduction or cessation if they occur, as they may be irreversible. The 2019 consensus statement specifically lists these as absolute indications to stop therapy [4].

Polycythemia is a risk with testosterone in men but is rarely clinically significant at female doses. Still, checking hematocrit at baseline and at 6 months is standard practice [3].

Special Populations and Contraindications

Women with active or history of hormone receptor-positive breast cancer should not receive testosterone cream without explicit oncology clearance [4]. The risk-benefit calculation changes significantly in this population, and the 2019 consensus statement explicitly states the evidence is insufficient to support use in this group [4].

Women with baseline androgenic alopecia, polycystic ovary syndrome (PCOS), or elevated DHEA-S should have a lower starting dose (0.25 to 0.3 mg/day) and shorter titration intervals (every 4 weeks initially) [6].

Premenopausal women requesting testosterone for HSDD represent a more complex scenario. The 2019 consensus found the evidence insufficient to recommend testosterone in this group, partly because premenopausal normal ranges are not as well established and partly because confounders are harder to separate from hormonal causes [4]. A small 2021 RCT published in the Journal of Sexual Medicine (N=48) found transdermal testosterone at 0.5 mg/day improved FSFI scores in premenopausal women with HSDD at 12 weeks, but larger trials are needed before this becomes a standard indication [17].

Compounding Pharmacy Considerations

Because no FDA-approved testosterone product is labeled for women at these doses, all female testosterone cream is compounded. Compounding quality varies. The FDA's guidance on compounding under Section 503A of the FD&C Act requires that compounded drugs be prepared for an identified individual patient based on a valid prescription, using pharmaceutical-grade ingredients, and by a licensed pharmacist [18]. Prescribers should request a certificate of analysis (CoA) from the compounding pharmacy confirming potency, sterility (if applicable), and absence of endotoxins.

PCAB (Pharmacy Compounding Accreditation Board) accreditation is a useful proxy for quality but is not federally mandated. Dose variability in compounded products is real: a 2012 audit of compounded testosterone creams found potency ranging from 67% to 270% of labeled dose across pharmacies [19]. Working with a PCAB-accredited pharmacy and checking CoAs mitigates this variability.

Integrating Testosterone Cream into a Telehealth HRT Consultation

Remote HRT management requires the same lab infrastructure as in-office care. At minimum, patients need a baseline testosterone panel (total testosterone by LC-MS/MS, free testosterone, SHBG), a basic metabolic panel, and a lipid panel before starting testosterone cream. Most telehealth platforms can order these through national lab networks such as Quest or LabCorp [4].

Follow-up labs at 6 weeks post-initiation are non-negotiable. Symptom questionnaires (FSFI, Menopause Rating Scale) can be completed digitally and scored automatically, giving the prescribing clinician a standardized measure of response rather than a narrative description [20].

The practical reality in telehealth is that some women self-adjust doses between visits. Patients should be counseled explicitly: do not increase the testosterone dose more than once between scheduled visits, and do not exceed 2 mg/day without a confirmed low serum level. Above 2 mg/day, the risk-benefit ratio requires an in-person or detailed video review with the clinician, not a patient-initiated adjustment.